GB201417094D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201417094D0
GB201417094D0 GBGB1417094.8A GB201417094A GB201417094D0 GB 201417094 D0 GB201417094 D0 GB 201417094D0 GB 201417094 A GB201417094 A GB 201417094A GB 201417094 D0 GB201417094 D0 GB 201417094D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1417094.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1417094.8A priority Critical patent/GB201417094D0/en
Publication of GB201417094D0 publication Critical patent/GB201417094D0/en
Priority to RU2017114355A priority patent/RU2692775C2/en
Priority to PCT/EP2015/071782 priority patent/WO2016046230A1/en
Priority to US15/514,416 priority patent/US10144733B2/en
Priority to BR112017006242A priority patent/BR112017006242A2/en
Priority to EP15767478.9A priority patent/EP3197894B1/en
Priority to KR1020177007736A priority patent/KR20170053638A/en
Priority to AU2015320863A priority patent/AU2015320863B2/en
Priority to CA2962321A priority patent/CA2962321A1/en
Priority to CN201580052204.2A priority patent/CN107074851B/en
Priority to ES15767478T priority patent/ES2811119T3/en
Priority to JP2017516367A priority patent/JP6657196B2/en
Priority to US16/165,506 priority patent/US10513517B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
GBGB1417094.8A 2014-09-26 2014-09-26 Novel compounds Ceased GB201417094D0 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds
JP2017516367A JP6657196B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as αvβ6 integrin antagonists for treatment of fibrotic diseases and the like
KR1020177007736A KR20170053638A (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
PCT/EP2015/071782 WO2016046230A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
US15/514,416 US10144733B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases
BR112017006242A BR112017006242A2 (en) 2014-09-26 2015-09-22 naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of, for example, fibrotic disorders
EP15767478.9A EP3197894B1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
RU2017114355A RU2692775C2 (en) 2014-09-26 2015-09-22 Naphthyridin derivatives as antagonists of alpha v beta 6 integrin for treating, in particular, fibrotic diseases
AU2015320863A AU2015320863B2 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
CA2962321A CA2962321A1 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of e.g. fibrotic diseases
CN201580052204.2A CN107074851B (en) 2014-09-26 2015-09-22 As αvβ6Naphthyridine derivatives of integrin antagonists for the treatment of e.g. fibrotic diseases
ES15767478T ES2811119T3 (en) 2014-09-26 2015-09-22 Naphthyridine derivatives as alpha v beta 6 integrin antagonists for the treatment of, for example, fibrotic diseases
US16/165,506 US10513517B2 (en) 2014-09-26 2018-10-19 Naphthyridine derivatives as alpha V beta 6 integrin antagonists for the treatment of E.G. fibrotic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1417094.8A GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
GB201417094D0 true GB201417094D0 (en) 2014-11-12

Family

ID=51901231

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1417094.8A Ceased GB201417094D0 (en) 2014-09-26 2014-09-26 Novel compounds

Country Status (12)

Country Link
US (2) US10144733B2 (en)
EP (1) EP3197894B1 (en)
JP (1) JP6657196B2 (en)
KR (1) KR20170053638A (en)
CN (1) CN107074851B (en)
AU (1) AU2015320863B2 (en)
BR (1) BR112017006242A2 (en)
CA (1) CA2962321A1 (en)
ES (1) ES2811119T3 (en)
GB (1) GB201417094D0 (en)
RU (1) RU2692775C2 (en)
WO (1) WO2016046230A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2017157735A1 (en) 2016-03-15 2017-09-21 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
AU2017359030A1 (en) * 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Pyrrole amides as alpha v integrin inhibitors
PT3538525T (en) 2016-11-08 2022-08-16 Bristol Myers Squibb Co 3-substituted propionic acids as alpha v integrin inhibitors
CA3042710A1 (en) 2016-11-08 2018-05-17 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
AU2017359028A1 (en) 2016-11-08 2019-06-20 Bristol-Myers Squibb Company Azole amides and amines as alpha V integrin inhibitors
EP3538519B1 (en) 2016-11-08 2021-07-28 Bristol-Myers Squibb Company Indazole derivatives as alpha v integrin antagonists
EP3558303A4 (en) 2016-12-23 2020-07-29 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
AU2018227417B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
RU2769702C2 (en) 2017-02-28 2022-04-05 Морфик Терапьютик, Инк. Avb6 integrin inhibitors
ES2904645T3 (en) 2017-11-07 2022-04-05 Bristol Myers Squibb Co Pyrrolopyrazine derivatives as alpha v integrin inhibitors
EP3844162A4 (en) * 2018-08-29 2022-05-25 Morphic Therapeutic, Inc. INHIBITORS OF av beta6 INTEGRIN
EP4086254A1 (en) 2018-08-29 2022-11-09 Morphic Therapeutic, Inc. Integrin inhibitors
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
BR0011108A (en) 1999-06-02 2002-03-19 Merck & Co Inc Compound, pharmaceutical composition, and processes of eliciting an integrin receptor antagonizing effect, treating or preventing osteoporosis, treating or preventing a condition mediated by antagonism of an integrin receptor, inhibiting bone resorption in a mammal in need for it, and treatment of tumor development
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc Integrin receptor antagonists
WO2001024797A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
SK8012002A3 (en) 1999-11-08 2002-10-08 Merck & Co Inc Process for the preparation of imidazolidinone alfagammabeta3/alfagammabeta5 integrin antagonists and intermediates obtained by this method
US7119098B2 (en) * 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
DE60126496T2 (en) 2000-07-26 2007-11-15 Merck & Co., Inc. ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
WO2002053099A2 (en) 2001-01-03 2002-07-11 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (en) 2001-03-16 2002-09-26 Merck Patent Gmbh New 3-acylamino-3-phenyl-propionic acid derivatives, are integrin inhibitors useful e.g. for treating thrombosis, cardiac infarction, angina pectoris, tumor diseases, inflammation, osteoporosis or infections
AR037517A1 (en) 2001-11-05 2004-11-17 Novartis Ag DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US20050043344A1 (en) 2002-12-20 2005-02-24 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists derivatives
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
AU2008231385B2 (en) 2007-03-23 2012-02-02 Amgen Inc. Delta3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase ( PI3K) inhibitors
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EP2211615A4 (en) 2007-10-22 2010-10-13 Glaxosmithkline Llc Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2011111880A1 (en) 2010-03-08 2011-09-15 주식회사 메디젠텍 Pharmaceutical composition for treating or preventing diseases caused by the nuclear export of gsk3, including a compound for inhibiting the nuclear export of gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
EP3052515A4 (en) 2013-09-30 2017-03-15 The Regents of the University of California Anti-alphavbeta1 integrin compounds and methods
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
JP2018510139A (en) 2015-02-19 2018-04-12 サイフルーア ライフ サイエンシズ インコーポレイテッド Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and methods of use thereof
CA2981371A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
EP3197894B1 (en) 2020-06-03
RU2692775C2 (en) 2019-06-27
US10513517B2 (en) 2019-12-24
BR112017006242A2 (en) 2017-12-12
US20170291899A1 (en) 2017-10-12
CN107074851A (en) 2017-08-18
JP2017528504A (en) 2017-09-28
RU2017114355A (en) 2018-10-29
WO2016046230A1 (en) 2016-03-31
US20190048005A1 (en) 2019-02-14
ES2811119T3 (en) 2021-03-10
AU2015320863A1 (en) 2017-03-09
CA2962321A1 (en) 2016-03-31
EP3197894A1 (en) 2017-08-02
KR20170053638A (en) 2017-05-16
RU2017114355A3 (en) 2019-01-14
AU2015320863B2 (en) 2018-09-06
CN107074851B (en) 2020-01-10
US10144733B2 (en) 2018-12-04
JP6657196B2 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
IL250345A0 (en) Novel compounds
IL250592A0 (en) Novel compounds
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
GB201402431D0 (en) Compounds
AP2016009432A0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201411236D0 (en) Novel compounds
GB201404987D0 (en) Compounds
GB201404002D0 (en) Novel compounds
GB201406591D0 (en) Compounds
GB201406956D0 (en) Compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
IL248983A0 (en) Novel compounds
GB201419102D0 (en) Novel compounds
GB201405361D0 (en) Compounds
ZA201605726B (en) Novel compounds
GB201421834D0 (en) Novel compounds
GB201421784D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds
GB201417021D0 (en) Novel compounds
GB201417043D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)